{
  "schema_version": 1,
  "document_code": "MHA-MCL-2026-v2.1",
  "supersedes": "MHA-MCL-2026-v2.0",
  "evidence_cut_off": "2026-07-30",
  "access_cut_off": "2026-07-30",
  "independent_clinical_review": "PASS",
  "pharmacy_verification": "COMPLETE",
  "verifier_identities": "RETAINED_PRIVATELY",
  "owner_production_direction": "REPLACE_V2_ON_WEBSITE",
  "exact_production_hash_ratification": "RATIFIED",
  "official_excalidraw_render_gate": "PASS",
  "offline_axe": "PASS \u2014 axe-core 4.10.2, WCAG 2.0/2.1 A and AA plus best-practice, 0 violations at 1280px and 375px",
  "outstanding_at_publication": [
    "Published correction against S38 (SYMPATICO) not retrieved; marked at every point of use.",
    "Published correction against S20C (sonrotoclax) not retrieved; marked at every point of use.",
    "ESMO 2025 and NCCN mantle cell sections were not retrievable; the society comparison covers EHA-EU 2025, BSH 2023 and EBMT 2026 only.",
    "Company early-access schemes are owner-attested and not independently documented.",
    "Access and regulatory positions are volatile and require scheduled re-checking."
  ],
  "ratified_candidate_manifest_sha256": "fe1e0411076f9e24422be55fcee9ea58beff8a8ef2436b5ed1965230678c6603",
  "publication_authority": true,
  "published": "2026-07-31",
  "supersedes_retained_at": "guidelines/mcl/superseded/v2.0/",
  "review_due": "The access and regulatory layer is volatile: NICE, SMC and commissioning positions in this guideline were checked on 2026-07-30 and require scheduled re-checking."
}